Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for VistaGen Therapeutics, Inc. (VTGN : NSDQ)

• Company Description    VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. Number of Employees: 57

• Price / Volume Information    Yesterday's Closing Price: $2.00 Daily Weekly Monthly 20 Day Moving Average: 187,024 shares Shares Outstanding: 29.16 (millions) Market Capitalization: $58.31 (millions) Beta: 0.61 52 Week High: $4.21 52 Week Low: $1.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.25% -19.02% 12 Week -5.66% -19.42% Year To Date -32.20% -36.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 343 ALLERTON AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-577-3600 fax: 888-482-2602 markmcp@vistagen.com http://www.vistagen.com

• General Corporate Information    Officers Shawn K. Singh - Chief Executive Officer; and Director Margaret M. FitzPatrick - Chairman Cynthia L. Anderson - Chief Financial Officer and Treasurer Ann M. Cunningham - Director Joanne Curley - Director Peer Information VistaGen Therapeutics, Inc. (CORR.) VistaGen Therapeutics, Inc. (RSPI) VistaGen Therapeutics, Inc. (CGXP) VistaGen Therapeutics, Inc. (BGEN) VistaGen Therapeutics, Inc. (GTBP) VistaGen Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92840H400 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 29.16 Most Recent Split Date: 6.00 (0.03:1) Beta: 0.61 Market Capitalization: $58.31 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.80 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.82 Price/Cash Flow: - Price / Sales: 83.55 EPS Growth vs. Year Ago Period: -72.00% vs. Previous Quarter: 6.52% Sales Growth vs. Year Ago Period: -43.07% vs. Previous Quarter: 27.87% ROE 06/30/25 - - 03/31/25 - -58.88 12/31/24 - -48.12 ROA 06/30/25 - - 03/31/25 - -52.38 12/31/24 - -43.80 Current Ratio 06/30/25 - - 03/31/25 - 6.51 12/31/24 - 9.35 Quick Ratio 06/30/25 - - 03/31/25 - 6.51 12/31/24 - 9.35 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -6,777.08 Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -6,777.08 Pre-Tax Margin 06/30/25 - - 03/31/25 - -10,578.40 12/31/24 - -6,775.93 Book Value 06/30/25 - - 03/31/25 - 2.44 12/31/24 - 2.91 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©